The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
Autoři | |
---|---|
Rok publikování | 2022 |
Druh | Konferenční abstrakty |
Fakulta / Pracoviště MU | |
Citace |